<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05099614</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00005944</org_study_id>
    <secondary_id>1914873</secondary_id>
    <nct_id>NCT05099614</nct_id>
  </id_info>
  <brief_title>Naloxone Auto-injection in Healthy Volunteers</brief_title>
  <official_title>Naloxone Administration Via Auto-injection in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>U.S. National Science Foundation</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study continues the work to develop a mobile breathing monitoring system to detect&#xD;
      slowed breathing and overdose events caused by opioid use. This is a single-site feasibility&#xD;
      study designed to test the mobile application with a commercially available drug delivery&#xD;
      device called the SmartDose by West Pharmaceuticals, Inc. The SmartDose is a wearable&#xD;
      self-injection device that can deliver a drug under the skin with a push of a button.&#xD;
      Naloxone is a drug used to reverse the effects of opioid drugs in the body. This study will&#xD;
      evaluate if the mobile application can wireless trigger the delivery of a small dose of&#xD;
      naloxone to a healthy adult volunteer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 10, 2021</start_date>
  <completion_date type="Actual">April 5, 2021</completion_date>
  <primary_completion_date type="Actual">April 5, 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Detection of slowed breathing that triggers the successful actuation of the auto-injector</measure>
    <time_frame>The participant breathes to 8 breaths per minute and the breath hold (15 - 30 seconds) triggers the auto-injector. This will take place over 1 -3 minutes.</time_frame>
    <description>Ability of the accelerometer-based system to detect slowed breathing and trigger the successful auto injection of medication</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of naloxone in blood samples</measure>
    <time_frame>Blood sampling at 3 and 8 minutes after the auto injector is triggered</time_frame>
    <description>The concentration of naloxone in the plasma is measured by blood at two time points</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Overdose Antidote</condition>
  <arm_group>
    <arm_group_label>Healthy adults</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy adults will receive 1.2 mg of naloxone hydrochloride injection solution, administered once via a wearable auto-injector, West Pharma SmartDose Generation I system. The respiratory sensing system under study is used to detect slowed breathing for the purpose of triggering the administration of the naloxone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Naloxone hydrochloride injection solution, SmartDose wearable auto injector and mobile respiratory sensing system</intervention_name>
    <description>1.2 mg of naloxone hydrochloride is administered to healthy adults using the SmartDose wearable auto injector and the mobile respiratory sensing system.</description>
    <arm_group_label>Healthy adults</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male/female volunteers&#xD;
&#xD;
          -  &gt;18 years&#xD;
&#xD;
          -  No allergy to naloxone or ingredients in its formulation&#xD;
&#xD;
          -  Ability to read and understand English&#xD;
&#xD;
          -  Written informed consent obtained from subject&#xD;
&#xD;
          -  Ability to comply with study requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of alcohol or substance abuse&#xD;
&#xD;
          -  History of unusual pain sensitivity, lack of sensitivity&#xD;
&#xD;
          -  History of chronic myofascial, inflammatory, neuropathic pain&#xD;
&#xD;
          -  Chronic use of medication known to interfere with naloxone&#xD;
&#xD;
          -  Pregnant women and nursing mothers&#xD;
&#xD;
          -  Presence of a condition or abnormality that in the opinion of the Principal&#xD;
             Investigator would compromise subject safety or the quality of the data (e.g., persons&#xD;
             with liver disease, renal insufficiency/failure)&#xD;
&#xD;
          -  Alcohol on the breath&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacob Sunshine, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 19, 2021</study_first_submitted>
  <study_first_submitted_qc>October 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2021</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Jacob Sunshine</investigator_full_name>
    <investigator_title>Associate Professor, School of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Drug Overdose</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naloxone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

